Abstract: The present invention relates generally to the use of gene mutations, whose presence or absence are useful for predicting a patient's response to treatment with an anti-proliferative agent, in particular a WEE1 inhibitor. The presence or absence of a mutation to the TP53 gene, can be used to predict response to treatment with a WEE1 inhibitor in a patient presenting with a cancerous condition.

Abstract: The present invention relates generally to the use of gene mutations, whose presence or absence are useful for predicting a patient's response to treatment with an anti-proliferative agent, in particular a WEE1 inhibitor. The presence or absence of a mutation to the TP53 gene, can be used to predict response to treatment with a WEE1 inhibitor in a patient presenting with a cancerous condition.

Abstract: The present invention relates generally to the use of gene mutations, whose presence or absence are useful for predicting a patient's response to treatment with an anti-proliferative agent, in particular a WEE1 inhibitor. The presence or absence of a mutation to the TP53 gene, can be used to predict response to treatment with a WEE1 inhibitor in a patient presenting with a cancerous condition.

Abstract: The invention is directed to methods, reagents, and kits for the detection of MAPK/ERK pathway mutations in a patient diagnosed for cancer. In one embodiment, the invention comprises a sensitive and selective method to identify mutations to the BRAF, KRAS, and NRAS genes in a single reaction. In another aspect of this embodiment, the invention comprises primers and probes for the detection of the BRAF, KRAS, and NRAS mutations using a single nucleotide primer extension assay. In another embodiment the invention is used to identify and select patients amenable for treatment with an ERK inhibitor.

Abstract: The present invention relates generally to the use of gene mutations, whose presence or absence are useful for predicting a patient's response to treatment with an anti-proliferative agent, in particular a WEE1 inhibitor. The presence or absence of a mutation to the TP53 gene, can be used to predict response to treatment with a WEE1 inhibitor in a patient presenting with a cancerous condition.

Abstract: The invention is directed to methods, reagents, and kits for the detection of MAPK/ERK pathway mutations in a patient diagnosed for cancer. In one embodiment, the invention comprises a sensitive and selective method to identify mutations to the BRAF, KRAS, and NRAS genes in a single reaction. In another aspect of this embodiment, the invention comprises primers and C probes for the detection of the BRAF, KRAS, and NRAS mutations using a single nucleotide primer extension assay. In another embodiment the invention is used to identify and select patients amenable for treatment with an ERK inhibitor.

Abstract: Methods and devices are disclosed for microarray analysis. In one embodiment a method is disclosed for processing a non-standard size slide having an array of chemical compounds attached to a surface of the slide. A sample is exposed to the surface of the non-standard size slide wherein components in the sample bind to the chemical compounds on the surface of the slide. The sample and the slide are incubated under conditions for carrying out the binding reactions, and the surface of the non-standard size slide is examined for the results of the binding reactions. Prior to the exposing step or the incubating step or the examining step, the non-standard size slide is placed into a slide holder comprising a slide-holding section a slide-holding section adapted to dispose the non-standard size slide to a processing instrument in a manner similar to that for a standard size slide. The non-standard size slide may also include an identifier such as a bar code.

Abstract: Methods and devices are disclosed for microarray analysis. In one embodiment a method is disclosed for processing a non-standard size slide having an array of chemical compounds attached to a surface of the slide. A sample is exposed to the surface of the non-standard size slide wherein components in the sample bind to the chemical compounds on the surface of the slide. The sample and the slide are incubated under conditions for carrying out the binding reactions, and the surface of the non-standard size slide is examined for the results of the binding reactions. Prior to the exposing step or the incubating step or the examining step, the non-standard size slide is placed into a slide holder comprising a slide-holding section a slide-holding section adapted to dispose the non-standard size slide to a processing instrument in a manner similar to that for a standard size slide. The non-standard size slide may also include an identifier such as a bar code.

Abstract: The present invention relates to the characterization of genes and their gene products (i.e., proteins). In particular, the invention relates to novel systems and methods for characterizing the cellular function and/or activity of different cellular constituents such as different genes and/or their gene products. The invention also provides novel systems and methods for comparing different cellular constituents (e.g., novel genes and/or their gene products) from different cells, such as genes and/or gene products from cells of different species of organism or, alternatively, from different cells (e.g., of different cell types or from different tissues types) of the same organism. In particular, using the systems and methods of the invention, it is possible to identify different cellular constituents having common cellular functions.